Who are RT plus Cisplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Weekly TC Chemotherapy, Intensified chemotherapy, Fludarabine and Melphalan, FOLFOX/XELOX/Capecitabine, Chemotherapy/Radiation, Gemcitabine + S-1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rt-plus-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

RT plus Cisplatin — Competitive Intelligence Brief

RT plus Cisplatin (RT plus Cisplatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytotoxic chemotherapy. Area: Oncology.

phase 3 Cytotoxic chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

RT plus Cisplatin (RT plus Cisplatin) — Sun Yat-sen University. RT plus Cisplatin works by combining radiation therapy with a chemotherapy drug to kill cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RT plus Cisplatin TARGET	RT plus Cisplatin	Sun Yat-sen University	phase 3	Cytotoxic chemotherapy
Weekly TC Chemotherapy	Weekly TC Chemotherapy	Jiangsu Cancer Institute & Hospital	phase 3	Cytotoxic chemotherapy
Intensified chemotherapy	Intensified chemotherapy	Italian Sarcoma Group	phase 3	Cytotoxic chemotherapy combination
Fludarabine and Melphalan	Fludarabine and Melphalan	First Affiliated Hospital of Zhejiang University	phase 3	Cytotoxic chemotherapy combination (purine analog + alkylating agent)
FOLFOX/XELOX/Capecitabine	FOLFOX/XELOX/Capecitabine	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	phase 3	Cytotoxic chemotherapy combination regimen	Thymidylate synthase (5-FU component); DNA (oxaliplatin component)
Chemotherapy/Radiation	Chemotherapy/Radiation	Hamilton Health Sciences Corporation	phase 3	Cytotoxic chemotherapy and ionizing radiation
Gemcitabine + S-1	Gemcitabine + S-1	AstraZeneca	phase 3	Cytotoxic chemotherapy combination	Ribonucleotide reductase, DNA polymerase, thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytotoxic chemotherapy class)

Jiangsu Cancer Institute & Hospital · 1 drug in this class
Sanofi · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RT plus Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/rt-plus-cisplatin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab